← Research library

Cerebrolysin for acute ischaemic stroke

Review of earlier studies · 2023

What was studied
Cochrane review: 7 RCTs, including one Cortexin trial with 272 participants
Main finding
The pooled mortality analysis of Cerebrolysin or Cortexin found probably little or no difference (RR 0.96, 95% CI 0.65–1.41; 6 trials, 1,689 participants).

Reported findings and study design

2023 Cochrane review: seven randomized trials, 1,773 participants; includes a 272-person Cortexin trial. Mortality analysis: six trials, 1,689 participants.

Population or model Cochrane review: 7 RCTs, including one Cortexin trial with 272 participants

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
All-cause mortalityRR 0.96; 95% CI 0.65–1.41Cerebrolysin/Cortexin pooled; moderate-certainty evidence
Non-death attritionRR 0.72; 95% CI 0.38–1.39Six trials, 1,689; very low certainty
Any serious adverse eventRR 1.16; 95% CI 0.81–1.66Cerebrolysin: three trials, 1,335
Fatal serious adverse eventRR 0.90; 95% CI 0.59–1.38Cerebrolysin: three trials, 1,335
Nonfatal serious adverse eventRR 2.39; 95% CI 1.10–5.23Cerebrolysin: three trials, 1,335
Nonfatal SAE: 30 mL/day for ten days subgroupRR 2.87; 95% CI 1.24–6.69Two trials, 1,189; cumulative dose 300 mL
Any adverse eventRR 1.03; 95% CI 0.92–1.14Four trials, 1,607

Mortality mixes two preparations; the serious-event estimates concern Cerebrolysin. A risk ratio whose interval crosses 1 is not a proven reduction or increase. Underlying trials overlap other pages.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • The pooled estimate is not Cortexin-only.
  • The potential increase in nonfatal serious adverse events concerned Cerebrolysin and should not automatically be assigned to Cortexin.

Source details

Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.

Sources checked

Citation

ReviewEnglish abstract

Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke Cochrane Database Syst Rev 10:CD007026. PMID 37818733

Study source ↗ · DOI 10.1002/14651858.cd007026.pub7 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards